High content screening in neurodegenerative diseases.
Bottom Line: It is expected that disease phenotypes are the result of multiple interactions that have been disrupted.This underestimation could, in part, explain the low success rate of drug approval due to undesirable or toxic side effects.This could subsequently be utilized to advance our understanding of the genome, the pathways involved in disease pathogenesis as well as identify potential therapeutic targets.
Affiliation: Department of Clinical Genetics, VU University Medical Center. firstname.lastname@example.orgShow MeSH
Related in: MedlinePlus
Affiliation: Department of Clinical Genetics, VU University Medical Center. email@example.com